Journal article

Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma

Kevin VS Tan, Benjamin Namdarian, Anthony J Costello, Christopher M Hovens

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | ELSEVIER SCIENCE INC | Published : 2011

Abstract

Each year, renal cell carcinoma (RCC) accounts for significant mortality in the population. Whilst the disease is now being diagnosed earlier, determining patient prognosis remains a challenge. Current prognostic indicators, such as TNM stage, Fuhrman grade, and RCC subtype, are inadequate. Unlike several other malignancies, RCC lacks a biomarker that can stratify patients into high, intermediate, or low risk for developing metastases. Additionally, antiangiogenic therapy is currently offered to patients with metastatic disease, however, a biomarker to monitor treatment efficacy is lacking. Recent attention has focused on surrogate markers of tumor vascularization as a source of prognostic b..

View full abstract